高陽科技(00818.HK)正考慮重啟建議分拆兆訊恆達
格隆匯1月11日丨高陽科技(00818.HK)發佈公吿,就建議分拆兆訊恆達並於上交所科創板單獨上市事項,公司目前正考慮重啟建議分拆,且公司於2023年1月11日為此向香港聯交所提交有關建議分拆的新申請,以待根據上市規則第15項應用指引批准。
自2022年五月起及於本公佈日期,集團持有兆訊恆達約45.73%權益,兆訊恆達入賬列作公司的聯營公司,且就上市規則第15項應用指引而言將被視為公司的附屬公司處理。兆訊恆達主要從事於中國銷售信息安全芯片及解決方案、計算機硬件及軟件、系統綜合及發展系統芯片(SOC)。概無法保證香港聯交所將批准建議分拆。於本公佈日期,兆訊恆達尚未向中國任何有關監管機構提交任何正式上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.